Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Allegro NV currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct examiner and 1 distinct art unit. The portfolio's current activity is limited to this 1 matter, suggesting a specific or early-stage focus. Practitioners should note that the 1 distinct art unit involved indicates a specialized focus within the biotechnology field. The concentration of the portfolio means that the company's immediate patent strategy is concentrated on 1 point of contact within the patent office.
The busiest examiner is GOTFREDSON, GAREN, who is responsible for 1 pending office action. Since this is the 1 pending action for the company, this 1 examiner is the sole point of contact for active prosecution. The outcome of this 1 case will determine the current status of the company's patent efforts in this technology area. This centralization allows for a targeted approach to prosecution, as all efforts are directed toward satisfying the requirements of GOTFREDSON, GAREN. Building a clear record with this 1 examiner is the primary task for the company's current prosecution efforts. Practitioners can focus exclusively on the preferences of this 1 examiner to advance the 1 pending application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOTFREDSON, GAREN | 1 | 40.0% | +28.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19538898 | INJECTABLE HYDROGEL | GOTFREDSON, GAREN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19538898 | INJECTABLE HYDROGEL | GOTFREDSON, GAREN | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19538898 | INJECTABLE HYDROGEL | GOTFREDSON, GAREN | 1619 | §102§103§112Other | Non-Final OA | — | Pending | Feb 12, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial